



Pharmacy Data: Actionable Information For Policy:

Maine-LD 1406, An Act To Promote Prescription Drug Price Transparency & Other Use Case Examples

LD 1406

An Act To Promote Prescription Drug Price Transparency- Requirements

Part I

By December 1, 2018 and annually thereafter,

The Maine Health Data Organization (MHDO) must produce a report that contains the following information about prescription drugs, both brand name and generic:

- A. The 25 most frequently prescribed drugs in the State;
- B. The 25 costliest drugs as determined by the total amount spent on those drugs in the State; and
- C. The 25 drugs with the highest year-over-year cost increases as determined by the total amount spent on those drugs in the State.

Data Source: MHDO's APCD

LD 1406- Requirements Part I

Pharmacy data that the MHDO has been collecting for years;

- MHDO has recently defined the methodology it will use to produce the report;
- MHDO will publicly report this information by including it in a tableau report on its website which will allow for comparisons over time.

LD 1406 – Requirements

Part II

Part II

MHDO is required to:

- develop a plan to collect data from manufacturers related to the cost and pricing of prescription drugs in order to provide transparency in and accountability for prescription drug pricing;
- consult with other state and national agencies and organizations to determine how to institute such data collection;
- submit the plan, its findings and any recommendations for suggested legislation to the Legislature no later than April 1, 2019.

LD 1406 - Requirements

Part II

Part II requirement-

- The National Academy For State Health Policy (NASHP) has established a workgroup of state officials charged with implementing pharmacy transparency laws and or studying the best approach to implementing this type of law.
- Maine (via MHDO) is one of seven states represented on the workgroup.
- NASHP released an RFP last month seeking a partner with expertise in this area to assist the states.
- RFP responses were submitted early October and are being evaluated now.

LD 1406- Requirements Part II

The primary goal of this project (NASHP, workgroup and successful bidder) is to create a roadmap and a template that a state can use to implement a database for prescription drug price information as required by states' transparency laws.

- The roadmap and database template will be the framework that multiple states can use (now and in the future) to create their prescription drug price transparency programs that include common terms, definitions and data points.

Other Use Cases for Pharmacy & Medical Claims Data in Maine's APCD

- Maine's APCD is the only comprehensive claims database in the state that includes common identifiers for medical claims and pharmacy claims.
 - Recent analysis of the match rate was 99% for Maine's largest commercial payers (which accounts for over 90% of the commercial market).
 - Specific Use Case Examples:
 - Maine CDC-wants to use the medical and pharmacy data to help with its strategies around antibiotic resistance & stewardship. We are currently testing the feasibility of identifying a specific medical diagnosis, like the common cold and then looking for a corresponding pharmacy claim for an antibiotic.
 - Several researchers want to use the medical and pharmacy claims data to analyze cancer rates and treatment, including prescription drugs.
 - MHDO has produced several reports for policy makers looking at specific medical diagnoses and a corresponding prescription for an opioid.